LUVOX CR

Compare LUVOX CR  to:
Compare
Compare

Generic Name for LUVOX CR

Fluvoxamine maleate 100mg, 150mg; ext-rel caps.

Legal Classification:

Rx

Pharmacological Class for LUVOX CR

SSRI.

Manufacturer of LUVOX CR

Jazz Pharmaceuticals

Indications for LUVOX CR

Obsessive-compulsive disorder. Social anxiety disorder.

Adult dose for LUVOX CR

Swallow whole. ≥18yrs: initially 100mg once daily at bedtime; may increase in 50mg increments at 1-week interval; range 100–300mg/day; max 300mg/day. Hepatic impairment: initially 100mg and titrate slowly.

Children's dosing for LUVOX CR

Not recommended.

Contraindications for LUVOX CR

Concomitant alosetron, tizanidine, pimozide, thioridazine, ramelteon. During or within 14 days of MAOIs.

Warnings/Precautions for LUVOX CR

Liver dysfunction. History of seizures (discontinue if occurs), mania/hypomania, or drug abuse. ECT. Cardiovascular disease. Diseases that affect metabolism or hemodynamic response. SIADH, edema, fluid loss, adrenal disorders, displacement syndromes (monitor electrolytes, BUN, creatinine). Reduced activity of CYP2D6. Suicidal tendencies. Reevaluate periodically. Write ℞ for smallest practical amount. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (Cat.C); 3rd trimester: consider tapering dose. Nursing mothers: not recommended.

Interactions for LUVOX CR

See Contraindications. Prolongation of QT interval with pimozide, thioridazine. Avoid alcohol. Potentiated by other serotonergic drugs, sumatriptan, lithium, tramadol, St. John's Wort. Concomitant other SSRIs, SNRIs, or tryptophan: not recommended. Potentiates diazepam (not recommended), triazolam and alprazolam (reduce their doses by at least ½), midazolam, theophylline (reduce its dose by ⅔ and monitor), warfarin, carbamazepine, tricyclic antidepressants (reduce their doses and monitor), propranolol, metoprolol (reduce their doses), clozapine, methadone, tacrine. Caution with drugs that inhibit CYP2D6 (eg, quinidine) or 3A4, phenytoin, diltiazem. Caution with aspirin, NSAIDs, warfarin, other anticoagulants (increased risk of bleeding). Monitor mexiletine levels. Smokers may have increased metabolism.

Adverse Reactions for LUVOX CR

Headache, somnolence, insomnia, nervousness, tremor, GI upset, anorexia, dry mouth, abnormal ejaculation, asthenia, sweating, decreased libido, rhinitis, anorgasmia, taste perversion; agitation, irritability, and behavioral changes (monitor).

How is LUVOX CR supplied?

Caps—30

Related Disease:

Obsessive-compulsive disorder
Social anxiety disorder

Related Resources

CDC issues statement and recommendations regarding prescription drug misuse

June 04, 2010

The CDC announced the 2009 National Youth Risk Behavior Survey (YRBS) found that 1 in 5 high school students have ever taken a prescription drug such as OxyContin (oxycodone, from Purdue), Percocet (oxycodone/acetaminophen, from Endo), Vicodin (hydrocodone/acetaminophen, from Abbott), Adderall (mixed salts of a single-entity amphetamine product, from Shire), Ritalin (methylphenidate, from Novartis), or Xanax (alprazolam, from Pfizer), without a prescription.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cymbalta approved for maintenance treatment of generalized anxiety disorder (GAD)

November 30, 2009

The FDA has approved Cymbalta (duloxetine HCl, from Lilly) for the maintenance treatment of generalized anxiety disorder (GAD) in adults.

Once-daily venlafaxine extended-release tablets available

August 19, 2009

Osmotica Pharmaceutical and Upstate Pharma, a subsidiary of UCB, have made available venlafaxine extended-release tablets in 37.5mg, 75mg, 150mg, and 225mg dosage strengths.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions